AbstractRhabdomyosarcoma (RMS) is the most common soft-tissue pediatric sarcoma. Treatment options remain limited, presenting an urgent need for novel therapeutic targets. Using a high-throughput siRNA screen against the human kinome, we identified GRK5, a G-protein receptor kinase, as a novel regulator of RMS tumor cell growth and self-renewal. Through functional assays in vitro and in vivo, we show that GRK5 regulates cell cycling in a kinase-independent manner to promote RMS tumor cell growth. GRK5 interacts with NFAT to facilitate autoregulation of NFAT1 expression in a kinase independent manner, and loss of NFAT1 phenocopies GRK5 loss-of-function effects on cell cycle arrest. Self-renewal of RMS, required for recapitulation of tumor heterogeneity, is significantly reduced with loss of GRK5 due to increased cell death. Treatment of human RMS xenografts in mice with CCG-215022, a GRK5-selective inhibitor, reduces tumor growth of RMS. GRK5 represents a novel therapeutic target for the treatment of RMS.Statement of SignificanceGRK5 promotes growth and self-renewal of RMS, thereby representing a novel therapeutic target for improving survival outcomes of RMS patients. GRK5 regulates RMS tumor cell growth in a kinase-independent manner through direct interaction with NFAT1. This finding promises novel drug design, targeting non-kinase domains of GRK5.
Characterization of GRK5 as a novel regulator of rhabdomyosarcoma tumor cell growth and self-renewal
